MYOS Appoints Christopher Pechock to Its Board of Directors
Company Bolsters Board With Addition of Wall Street and Investment Veteran
CEDAR KNOLLS, NJ-(Marketwired — Feb 24, 2014) — MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance («MYOS» or the «Company»), announced today that it has appointed Christopher Pechock to its Board of Directors.
«Chris brings broad experience to MYOS having built an exceptional track record during his career at a number of notable investment firms on Wall Street and has built a strong reputation in guiding a wide range of developing and growing companies. We believe his diverse expertise and extensive network will be invaluable to MYOS during this important stage in the Company’s history. Chris is a thoughtful and creative advisor, and on behalf of the Board of Directors and management, I would like to welcome him to the MYOS team," stated Robert J. Hariri, M.D., Ph. D., Chairman of the Board of MYOS Corporation.
«I believe MYOS is poised to become a leader in the field of muscle health," commented Mr. Pechock. «The Company has an innovative and exciting business strategy that can maximize the probability of success as an emerging biotherapeutics and bionutrition business. Given the Company’s growing consumer presence with leading sports nutrition products, I believe MYOS is perfectly positioned to apply its technology beyond the current bionutrition market to treat muscle loss associated with aging, chronic illness and a range of unmet medical needs. I am thrilled to be part of the team during this exciting time.»
Mr. Pechock brings to MYOS more than 25 years of Wall Street experience as an investment banker,
Mr. Pechock serves on the Boards of Directors of Oceanus LLC and Gleacher & Company. He previously served on various other Boards, including Renewable Biofuels, Comsys IT, Compass Aerospace, Goss International, Huntsman Corporation, XL Health Corporation, Leprechaun Holding Company, FXI Holdings, Icon Health and Fitness, and Spincycle, Inc.
About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of
The Company’s first commercial product